Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica

NCT07670546 is registered in ClinicalTrials.gov with R-Pharm International, LLC as lead sponsor.

NCT NCT07670546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07670546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica
Lead sponsor
R-Pharm International, LLC
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 11, 2025
Completion date
July 9, 2026
Enrollment
125 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

polymyalgia rheumatica